Skip to main content
Premium Trial:

Request an Annual Quote

MOgene Becomes Certified Agilent Microarray Service Provider

NEW YORK, Oct. 4 (GenomeWeb News) - Agilent Technologies has certified MOgene to become an microarray service provider, the companies said today -- the second company in North America to receive this kind a certification, the companies said today.

 

The certification validates MOgene's "ability to provide ... microarray processing and data analysis services" using Agilent microarrays, the companies said.

 

MOgene launched its microarray services business in March, and has offered research services using Agilent custom and catalog microarrays to researchers at universities, biotechnology and pharmaceutical companies, and agrochemical companies. 

 

Agilent certifies companies "once laboratory personnel complete a training program and the laboratory, as a whole, passes a rigorous set of assessments," the companies said.

 

To be eligible, a service laboratory "must analyze Agilent 60-mer microarrays on the complete Agilent gene expression platform" -- which comprises a microarray scanner, hybridization and labeling kits, feature extraction software, and one of the Rosetta gene expression data analysis systems.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.